Article
Plasma and stool metabolomics to identify microbiota derived-biomarkers of metabolic dysfunction-associated fatty liver disease: effect of PNPLA3 genotype.
Metabolomics : Official journal of the Metabolomic Society - 16 Jun 2021
Mazzini Flavia Noelia, Cook Frank, Gounarides John, Marciano Sebastián, Haddad Leila, Tamaroff Ana Jesica, Casciato Paola, Narvaez Adrián, Mascardi María Florencia, Anders Margarita, Orozco Federico, Quiróz Nicolás, Risk Marcelo, Gutt Susana, Gadano Adrián, Méndez García Celia, Marro Martin L, Penas-Steinhardt Alberto, Trinks Julieta
Abstract excerpt
INTRODUCTION: Non-invasive biomarkers are needed for metabolic dysfunction-associated fatty liver disease (MAFLD), especially for patients at risk of disease progression in high-prevalence areas. The microbiota and its metabolites represent a niche for MAFLD biomarker discovery. However, studies are not reproducible as the microbiota is variable. OBJECTIVES: We aimed to identify microbiota-derived metabolomic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
